U.S. markets close in 3 hours 35 minutes
  • S&P 500

    4,174.95
    -4.81 (-0.12%)
     
  • Dow 30

    34,149.08
    +95.14 (+0.28%)
     
  • Nasdaq

    12,193.03
    -7.79 (-0.06%)
     
  • Russell 2000

    1,998.18
    -3.04 (-0.15%)
     
  • Crude Oil

    74.20
    -1.68 (-2.21%)
     
  • Gold

    1,877.30
    -53.50 (-2.77%)
     
  • Silver

    22.42
    -1.19 (-5.04%)
     
  • EUR/USD

    1.0832
    -0.0079 (-0.73%)
     
  • 10-Yr Bond

    3.5120
    +0.1160 (+3.42%)
     
  • GBP/USD

    1.2083
    -0.0146 (-1.19%)
     
  • USD/JPY

    131.1320
    +2.5280 (+1.97%)
     
  • BTC-USD

    23,565.98
    -261.04 (-1.10%)
     
  • CMC Crypto 200

    539.04
    +2.18 (+0.41%)
     
  • FTSE 100

    7,901.80
    +81.64 (+1.04%)
     
  • Nikkei 225

    27,509.46
    +107.41 (+0.39%)
     

Nabriva's stock is up after sharing antibiotic news

Nabriva's stock is up after sharing antibiotic news

Shares of Nabriva Therapeutics Plc were up 13.8% in premarket trading on Monday after the company said in a news release it had positive data from a Phase 1 clinical trial assessing its antibiotic as a treatment for cystic fibrosis. The drug, Xenleta, is approved to treat community-acquired bacterial pneumonia. Nabriva plans to share more details from the open-label CF study in the first half of next year. The company's stock has tumbled 85.5% this year, while the broader S&P 500 is down 15.5%.